Australia's most trusted
source of pharma news
Tuesday, 13 May 2025
Posted 13 May 2025 AM
The latest twist in the unusual path to funding for a major new Novartis treatment has seen the Federal Government quietly agree to reimbursement for the therapy.
Novartis' radioligand therapy Pluvicto will be funded on the MBS for prostate cancer from July this year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.